News from chimerix, inc

Mar 28, 2013, 07:00 ET

Chimerix's Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantation's Annual Meeting

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations...

Mar 14, 2013, 07:00 ET

Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer

 Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that...

Mar 12, 2013, 07:00 ET

FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection

 Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the...

Mar 08, 2013, 17:10 ET

Chimerix Files Registration Statement for Proposed Initial Public Offering

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has...

Feb 20, 2013, 07:00 ET

Ernest Mario, Ph.D., Named Chairman of Chimerix, Inc.

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment...

Feb 19, 2013, 07:00 ET

Data Demonstrating the Safety and Efficacy of Chimerix's Antiviral CMX001 Presented at BMT Tandem Meetings

 Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from...

Feb 04, 2013, 07:00 ET

Data Related to Chimerix's Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings

 Chimerix, Inc., a biopharmaceutical company developing antivirals in areas of high unmet medical need, today announced that three abstracts...

Nov 26, 2012, 07:00 ET

Chimerix To Present At Therapeutic Area Partnerships Meeting

 Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive...

Nov 12, 2012, 09:00 ET

Chimerix Appoints Michelle Berrey Chief Medical Officer

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Michelle Berrey, MD, MPH, has...

Nov 12, 2012, 07:00 ET

Chimerix To Present At Two Upcoming Healthcare Conferences In November

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced presentations at two upcoming investor...

Sep 21, 2012, 12:56 ET

Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced data highlighting the significant...

Jul 24, 2012, 07:30 ET

Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV

 Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada,...

Jul 23, 2012, 10:37 ET

Chimerix's Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study

 Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the presentation of data showing...

Jul 09, 2012, 10:00 ET

Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at...

Apr 03, 2012, 10:00 ET

Chimerix to Present at Upcoming Needham and Future Leaders Conferences

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced presentations at two upcoming investor conferences...

Mar 05, 2012, 10:00 ET

Chimerix to Present at Cowen and Company's 32nd Annual Health Care Conference

 Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief...

Feb 06, 2012, 08:30 ET

Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients

 Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a...

Jan 25, 2012, 12:00 ET

Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that final data from CMX001 Study 201, a...

Nov 11, 2011, 12:06 ET

Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at...

Nov 09, 2011, 10:00 ET

Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that Kenneth I. Moch, President and...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Analysts Review